Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | GAA | P10253 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991171 | 0.84 | ALDH1A1 (0.61) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL48461 | 0.84 | PIK3CG (0.76) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL49804 | 0.83 | ABL1 (0.64) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL48393 | 0.83 | PIK3CG (0.74) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL48942 | 0.83 | PIK3CG (1.00) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL48767 | 0.83 | PIK3CD (0.66) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL12992093 | 0.82 | PIK3CG (0.74) | MAPTALDH1A1GAALMNAPIK3CG | |
| SCHEMBL48710 | 0.82 | PIK3CG (0.82) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL924922 | 0.82 | PIK3CG (0.61) | MAPTALDH1A1GAALMNAKDM4E | |
| SCHEMBL6546546 | 0.82 | MAPT (0.88) | MAPTALDH1A1GAALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144513-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | MAPT 1132/4885ALDH1A1 3271/4885GAA 2233/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | MAPT 1132/4885ALDH1A1 3271/4885GAA 2233/4885 |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CG, PIK3CD | MAPT 2849/4885ALDH1A1 4418/4885GAA 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.